Literature DB >> 28237646

Recurrence-associated genes in papillary thyroid cancer: An analysis of data from The Cancer Genome Atlas.

Ming-Nan Chien1, Po-Sheng Yang2, Jie-Jen Lee2, Tao-Yeuan Wang3, Yi-Chiung Hsu4, Shih-Ping Cheng5.   

Abstract

BACKGROUND: Recurrence of papillary thyroid cancer is not uncommon, but incorporating clinicopathologic parameters to predict recurrence is suboptimal. The aim of this study was to identify systemically recurrence-associated genes using The Cancer Genome Atlas RNA sequencing database.
METHODS: A total of 504 patients with transcriptome sequencing data of the primary neoplasm were included in this study. High and low levels of expression of each gene were defined by median splits. Differences in recurrence-free survival were compared using Kaplan-Meier curves and log-rank tests. Recurrence-associated genes were subjected to functional enrichment analyses with Kyoto Encyclopedia of Genes and Genomes annotation databases and Ingenuity Pathway Analysis.
RESULTS: We found that 1,807 genes were associated with recurrence-free survival. There were 676 genes of which high expression was associated with a greater risk of recurrence. These genes were enriched in pathways involved in cell cycle regulation and DNA repair. Among 1,131 genes of which low expression was associated with recurrence, Kyoto Encyclopedia of Genes and Genomes-annotated functions were metabolism, calcium signaling, glycan biosynthesis, and the Notch signaling pathway. Canonical pathways identified by Ingenuity Pathway Analysis included RXR function, nitric oxide signaling, interleukin-8 signaling, and nutrient sensing. In addition, low expression of the majority of thyroid differentiation genes was associated with a significantly less recurrence-free survival.
CONCLUSION: Upregulation of cell cycle-regulating and DNA repair genes appears to have a negative impact on recurrence-free survival in patients with papillary thyroid cancer. Furthermore, recurrence is associated with thyroid dedifferentiation.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28237646     DOI: 10.1016/j.surg.2016.12.039

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

1.  Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer.

Authors:  Chien-Liang Liu; Po-Sheng Yang; Ming-Nan Chien; Yuan-Ching Chang; Chi-Hsin Lin; Shih-Ping Cheng
Journal:  Histochem Cell Biol       Date:  2018-03-12       Impact factor: 4.304

2.  Overexpression of Histone H3 Lysine 27 Trimethylation Is Associated with Aggressiveness and Dedifferentiation of Thyroid Cancer.

Authors:  Chia-Chi Tsai; Ming-Nan Chien; Yuan-Ching Chang; Jie-Jen Lee; Shuen-Han Dai; Shih-Ping Cheng
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

3.  Propensity Score-Matched Analysis to Identify Pathways Associated with Loss of Sodium Iodide Symporter in Papillary Thyroid Cancer.

Authors:  Fang Lee; Chi-Yu Kuo; Chung-Hsin Tsai; Shih-Ping Cheng
Journal:  Curr Issues Mol Biol       Date:  2022-03-26       Impact factor: 2.976

4.  Transcriptomic Characteristics Associated With Aging in the Thyroid Gland.

Authors:  Chien-Liang Liu; Ming-Nan Chien; Yi-Chiung Hsu; Shih-Ping Cheng
Journal:  Front Nutr       Date:  2022-05-25

5.  Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer.

Authors:  Kung-Chen Ho; Jie-Jen Lee; Chi-Hsin Lin; Ching-Hsiang Leung; Shih-Ping Cheng
Journal:  Diagnostics (Basel)       Date:  2020-05-05

6.  Identification of Key Pathways and Genes in Anaplastic Thyroid Carcinoma via Integrated Bioinformatics Analysis.

Authors:  Shengqing Hu; Yunfei Liao; Lulu Chen
Journal:  Med Sci Monit       Date:  2018-09-14

7.  Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer.

Authors:  Mohammad Hussein; Lauren Mueller; Peter P Issa; Muhib Haidari; Lily Trinh; Eman Toraih; Emad Kandil
Journal:  Biomedicines       Date:  2022-08-16

8.  Heme Oxygenase-1 Inhibitors Induce Cell Cycle Arrest and Suppress Tumor Growth in Thyroid Cancer Cells.

Authors:  Po-Sheng Yang; Yi-Chiung Hsu; Jie-Jen Lee; Ming-Jen Chen; Shih-Yuan Huang; Shih-Ping Cheng
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

9.  Semaphorin 6A Attenuates the Migration Capability of Lung Cancer Cells via the NRF2/HMOX1 Axis.

Authors:  Li-Han Chen; Che-Yu Liao; Liang-Chuan Lai; Mong-Hsun Tsai; Eric Y Chuang
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.